Two trials that used PCWG-2 guidelines to define progression were analysed : a randomized phase II trial ( n = 221 ) comparing first-line docetaxel-prednisone plus AT-101 or placebo , and a phase III trial ( n = 873 ) comparing prednisone plus sunitinib or placebo after docetaxel-based chemotherapy .